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Abstract: Pyomyositis is a severe bacterial infection of skeletal muscle, commonly affecting 35 
children in tropical regions, predominantly caused by Staphylococcus aureus. To understand 36 
the contribution of bacterial genomic factors to pyomyositis, we conducted a genome-wide 37 
association study of S. aureus cultured from 101 children with pyomyositis and 417 children 38 
with asymptomatic nasal carriage attending the Angkor Hospital for Children, Cambodia. We 39 
found a strong relationship between bacterial genetic variation and pyomyositis, with estimated 40 
heritability 63.8% (95% CI 49.2-78.4%). The presence of the Panton-Valentine leucocidin 41 
(PVL) locus increased the odds of pyomyositis 130-fold (p=10
-17.9
). The signal of association 42 
mapped both to the PVL-coding sequence and the sequence immediately upstream. Together 43 
these regions explained over 99.9% of heritability (95% CI 93.5-100%). Our results establish 44 
staphylococcal pyomyositis, like tetanus and diphtheria, as critically dependent on a single 45 
toxin and demonstrate the potential for association studies to identify specific bacterial genes 46 
promoting severe human disease. 47 
  48 
 3 
Introduction 49 
Microbial genome sequencing and bacterial genome-wide association studies (GWAS) present 50 
new opportunities to discover bacterial genes involved in the pathogenesis of serious 51 
infections.
1-6
 Pyomyositis is a severe infection of skeletal muscle most commonly seen in 52 
children in the tropics.
7-9
 In up to 90% of cases it is caused by a single bacterial pathogen, 53 
Staphylococcus aureus (S. aureus).
7-10
 Unlike infections of the skin and superficial soft tissues, 54 
the skin and subcutaneous tissues are not usually involved in pyomyositis, by contrast to 55 
intense inflammation in the infected muscles.
7,8
 Pyomyositis is thought to arise from 56 
haematogenous seeding of bacteria from blood to muscle.
8
 There is evidence that some 57 
S. aureus strains have heightened propensity to cause pyomyositis – the incidence in the USA 58 
doubled during an epidemic of community-associated methicillin resistant S. aureus (CA-59 
MRSA)
11
 – but molecular genetic investigation of S. aureus from pyomyositis has been 60 
limited.
12
  61 
Panton-Valentine leucocidin (PVL), a well-known staphylococcal toxin causing purulent skin 62 
infections and found in epidemics caused by CA-MRSA, has been implicated in pyomyositis, 63 
pneumonia and other S. aureus disease manifestations, but its role in these invasive infections 64 
is disputed.
13-16
 PVL is a bipartite pore-forming toxin comprising the co-expressed LukF-PV 65 
and LukS-PV proteins.
17,18
 The coding sequence for PVL, lukSF-PV, is usually carried on 66 
bacteriophages,
13,17
 which facilitate lukSF-PV exchange between lineages.
19
 The mechanism of 67 
PVL toxicity has been shown to involve cell lysis in human myeloid cells, particularly 68 
neutrophils, by insertion into the cellular membrane,
21
 leading the tissue to release 69 
inflammatory neutrophil products.
 22
 Neutrophil lysis is mediated by PVL binding to target 70 
complement receptors C5aR; in binding, PVL has both toxic and immunomodulatory effects, as 71 
it also inhibits C5a mediated immune activation.
23
 72 
Although small case series testing for candidate genes have reported a high prevalence of PVL 73 
among pyomyositis-causing S. aureus,
11,23,24
 a detailed meta-analysis found no evidence for an 74 
increased rate of musculoskeletal infection (or other invasive disease) in PVL-positive bacteria 75 
versus controls.
13
 These conflicting results may reflect insufficiently powered studies, and 76 
some case series lack comparative control strains.
23
 A further problem with the use of candidate 77 
gene studies in studying pathogenesis is that they may miss important variation elsewhere in 78 
the genome. One study reporting a critical role for PVL in the causation of severe pneumonia
15
 79 
was later found to have overlooked mutations in key regulatory genes, capable of producing the 80 
virulence that had been attributed to PVL by the original study.
16
 Thus, while some evidence  81 
suggests an association between pyomyositis and PVL, there remains significant uncertainty 82 
regarding the bacterial genetic predisposition of S. aureus to pyomyositis, and whether PVL is 83 
an important virulence factor, or merely an epiphenomenon, carried by bacteria alongside 84 
unidentified genetic determinants.
25,26
  85 
GWAS offer a means to screen entire bacterial genomes to discover genes and genetic variants 86 
associated with disease risk. They are particularly appealing because they enable the 87 
investigation of traits not readily studied in the laboratory, and do not require the nomination of 88 
specific candidate genes.
5
 Proof-of-principle GWAS in bacteria have demonstrated the  89 
successful rediscovery of known antimicrobial resistance (AMR) determinants.
2,3,4
 However, 90 
AMR is under extraordinarily intense selection in bacteria. More subtle traits, including host 91 
specificity
1
 and the duration of pneumococcal carriage,
27
 have also been demonstrated using 92 
GWAS. Promising results for GWAS in human infecting bacteria include identifying possible 93 
loci for invasive infection with Streptococcus pyogenes
4 
and Staphylococcus epidermidis
28
,and 94 
the identification of virulence associated genes corresponding with regional differences in 95 
disease manifestations of melioidosis.
29 
Within species, lineage specific variants have been 96 
 4 
shown to predict mortality following S. aureus bacteraemia.
30
 These studies support the 97 
potential GWAS has to precisely pinpoint genes and genetic variants underlying the propensity 98 
to cause specific human infections, making it a promising tool to investigate the possible 99 
contribution of bacterial genomic variation to pyomyositis.  100 
Results 101 
To understand the bacterial genetic basis of pyomyositis, we sampled and whole-genome 102 
sequenced S. aureus from 101 pyomyositis infections and 417 asymptomatic nasal carriage 103 
episodes in 518 children attending Angkor Hospital for Children in Siem Reap, Cambodia 104 
between 2008 and 2012 (Supplementary File 1). As expected, we observed representatives of 105 
multiple globally common lineages in Cambodia, together with some globally less common 106 
lineages at high frequency, in particular clonal complex (CC) 121, identified by multi-locus 107 
sequence typing (MLST). There were no major changes in lineage frequency over time (Figure 108 
1-figure supplement 1). 109 
In our study, some S. aureus lineages were strongly overrepresented among cases of 110 
pyomyositis compared with asymptomatic, nasally-carried controls over the same time period. 111 
Notably, 86/101 (85%) of pyomyositis cases were caused by CC-121 bacteria, whereas no 112 
pyomyositis cases were caused by the next two most commonly carried lineages, sequence type 113 
(ST)-834 and CC-45 (Figure 1). We estimated the overall heritability of case/control status to 114 
be 63.8% (95% CI 49.2-78.4%) in the sample, reflecting the strong relationship between 115 
bacterial genetic variation and case/control status. We used bugwas
6
 to decompose this 116 
heritability into the principal components (PCs) of bacterial genetic variation. PC 1, which 117 
distinguished CC-121 (the most common pyomyositis lineage) from ST-834 (which was only 118 
found in carriage), showed the strongest association with case /control status (p = 10
-29.6
, Wald 119 
test). The strongest associations were with PC 20, which differentiated a sub-lineage of CC-121 120 
within which no cases were seen (p = 10
-13.9
), and PC 2, which distinguished CC-45 from the 121 
rest of the species (p =10
-4.9
).  122 
We conducted a GWAS to identify bacterial genetic variants associated with pyomyositis, 123 
controlling for differences in pyomyositis prevalence between S. aureus lineages. We used a 124 
kmer-based approach
1
 in which every variably present 31bp DNA sequence observed among 125 
the 518 genomes was tested for association with pyomyositis versus asymptomatic nasal 126 
carriage, controlling for population structure using GEMMA.
31
 These kmers captured bacterial 127 
genetic variation including single nucleotide polymorphisms (SNPs), insertions or deletions 128 
(indels), and presence or absence of entire accessory genes. We found 10.7 million unique 129 
kmers variably present across the bacterial genomes. In total, 9,175 kmers were significantly 130 
associated with case/control status after correction for multiple testing (10
-6.8
  p  10-21.4; 131 
Figure 2A). When mapped to the de novo assembly of a CC121 isolate from pyomyositis 132 
(PYO2134), the vast majority of these kmers (9,074/9,175; 98.9%) localised to a 45.7kb region 133 
spanning an integrated prophage with 95% nucleotide identity to SLT (Figure 2B). Most 134 
(9,173/9,175; 99.98%) significant kmers were found at an increased frequently in pyomyositis, 135 
with odds ratios (OR) ranging from 2.7 to 139.8, indicating that the presence of each was 136 
associated with increased risk of disease. The presence of bacteriophage SLT was thus 137 
strongly associated with pyomyositis.  138 
We were able to localise the most statistically significant signal of association to kmers that 139 
mapped within SLT to the lukS-PV and lukF-PV cargo genes. These genes encode the 140 
subunits of PVL, which multimerise into a pore-forming toxin capable of rapidly lysing the 141 
membranes of human neutrophils.
17,25
 1,630 kmers tagging the presence of the lukSF-PV 142 
coding sequences (CDS) were highly significantly associated with disease, being present in 143 
98/101 (97%) pyomyositis cases and 84/417 (20%) carriage controls (unadjusted OR 129.5, 144 
 5 
p=10
-17.9
). Kmers tagging variation in the 389bp region immediately upstream of the CDS were 145 
also strongly associated with disease (p=10
-21.4
). The most significant of these kmers were co-146 
present with the CDS in the same cases (98/101, 97.0%), but present in fewer controls (79/417, 147 
18.9%), producing an OR of 140.  148 
Closer examination of this ~400bp upstream region in genomes assembled from short-read 149 
Illumina sequencing showed that assembly of the region was problematic, with breaks or gaps 150 
in the assembly (Figure 2-figure supplement 2). To improve the accuracy of this region of the 151 
assembled genomes we performed long-read Oxford Nanopore sequencing on the 37 genomes 152 
with incomplete or discontinuous assembly upstream of the PVL CDS. By integrating long-153 
read and short-read data we were able to assemble a single contig spanning this region in all 154 
isolates (Figure 2-figure supplement 2). When these improved assemblies were introduced, the 155 
signal of association upstream of the PVL CDS was no more significant than within the CDS 156 
(Figure 2C). Therefore, the presence of genomic sequence spanning the PVL toxin-coding 157 
sequences and the upstream, presumed regulatory, region exhibited the strongest association 158 
with pyomyositis in the S. aureus genome. All isolates with kmers mapping to the PVL CDS 159 
had 98% or more coverage for the PVL CDS genes in de novo assembly (Figure 2-figure 160 
supplement 3). The signal of association in the earlier and later periods of the study were 161 
examined and found to be consistent (Figure 2-figure supplement 4).  162 
Out of 9,175 kmers significantly associated with pyomyositis, we only found 101 kmers related 163 
to regions outside the PVL-carrying prophage (Figure 2A, Supplementary File 2). Two kmers 164 
mapping at a position near 0.2Mb in the PYO2014 reference genome showed homology to 165 
platelet adhesin sraP by BLAST. Thirty-five kmers mapping to a 50bp non-coding fragment at 166 
0.6Mb and two kmers mapping to 2.8Mb showed homology to an MSSA476 intergenic 167 
sequence between adhesin-encoding sdrC and sdrD by BLAST. One kmer mapping to position 168 
2.0Mb showed no sequence homology by BLAST. Sixty-one kmers mapping to a 61bp non-169 
coding region at 2.7Mb showed homology to an MSSA476 intergenic sequence between 170 
acetyltransferase-encoding genes SAS2453 and SAS2454 by BLAST. In conclusion, these 171 
other signals were short, fragmentary and mostly non-coding so we did not investigate them 172 
further. 173 
The presence of high-risk kmers mapping to the PVL region explained the vast majority of 174 
observed heritability. When the presence or absence of the most significant kmer pattern, a set 175 
of kmers with an identical pattern of presence in the population, all of which mapped to the 176 
PVL region, was included as a covariate in GEMMA, the remaining heritability not explained 177 
by other factors was estimated and found to be 0.0% (95% CI 0-2.5%). Thus, the point estimate 178 
for heritability (not explained by the inclusion of PVL-tagging kmers) is reduced by 100% 179 
(95% CI 93.5-100%), meaning we have little evidence for any remaining heritability in 180 
case/control status.  181 
Presence or absence of the PVL region accounted for the differences in pyomyositis rates 182 
between lineages. It was common in pyomyositis-associated lineages including CC-121 and 183 
absent from carriage/non-pyomyositis-associated lineages including ST-834 and CC-45 184 
(Figure. 1), explaining over 99.9% of observed heritability in case-control status. It was 185 
infrequent in the non-pyomyositis-associated sub-lineage of CC-121 (2/36, 5.6%), and 186 
sporadically present in pyomyositis cases in otherwise non-pyomyositis-associated, PVL-187 
negative strains CC-1 and CC-88. Its absence from only three cases (in lineages CC-88, CC-1 188 
and CC-121) suggested that the PVL region approached necessity for development of 189 
pyomyositis in the current setting in Cambodian children, while its presence in 20% of controls 190 
indicated that PVL-associated pyomyositis is incompletely penetrant, i.e. presence of the PVL 191 
region does not always lead to disease. 192 
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PVL genes were carried on multiple genetic backgrounds in this population, and the phage 193 
backgrounds vary by clonal complex. We examined all assemblies for sequence similarity to 194 
six known bacteriophages that carry the PVL genes,
18
 as well as the 45.7kb region in 195 
PYO2134, a hypothesised integrated prophage identified in the reference genome prepared for 196 
this study, which we have called CC121 (Figure S4). The finding of PVL genes on BLAST 197 
corresponded completely with the presence of kmers mapping across the PVL locus. We find 198 
sequences with >95% homology to four of these seven phages in the population. Regions in 199 
some assemblies showed homology for multiple phages, reflecting the similarity between 200 
SLT, Sa2USA and CC121 rather than the presence of multiple phages, and resolution of 201 
phages was limited by fragmented assemblies from short reads (Supplementary File 3). Phage 202 
types were restricted within most lineages, with SLT found in ST-3206, Sa2USA in ST-203 
1232 and PVL in CC-1. CC121 was the phage most often identified in the dominant 204 
pyomyositis strain CC-121, but it was absent in all but one isolate from the low risk subclade 205 
within CC-121. Strikingly, PVL negative isolates in CC-121 and ST-834 strains frequently 206 
retained sequence homologous to >95% of SLT, suggesting that some PVL-negative CC-121 207 
isolates lost PVL secondarily by gene deletion rather than prophage excision.  208 
Discussion
 
209 
In this study we found a strong association between pyomyositis, a highly distinctive tropical 210 
infection of skeletal muscle in children, and Panton-Valentine leukocidin, a bacterial toxin 211 
commonly carried by bacteriophages. We found that a single coding region together with the 212 
upstream sequence are all but necessary for the development of pyomyositis: its sporadic 213 
presence is associated with pyomyositis in otherwise low-frequency strains, and its absence is 214 
associated with asymptomatic carriage in a high-propensity strain. PVL appears to be carried 215 
on multiple phage backgrounds in this population, but PVL-positive lineages generally carry a 216 
single phage type, as expected given the observed strain restriction of phages in S. aureus.
33,34
 217 
The locally common PVL-positive CC-121 lineage contributes most strongly to the prevalence 218 
of pyomyositis in Cambodian children. 219 
While PVL has long been thought an important S. aureus virulence factor,
35-37
 its role in 220 
invasive disease has been controversial,
25,26
 with conflicting results in case-control studies and 221 
an absence of supporting evidence on meta-analysis.
13
 In previous studies the PVL positive 222 
USA300 lineage was associated with musculoskeletal infection (both pyomyositis and 223 
osteomyelitis), however in these studies almost all such infections were caused by the USA300 224 
strain, so the role of PVL was almost completely confounded by both methicillin resistance and 225 
strain background.
11,36
 In our study, this confounding influence is broken down by the 226 
movement of PVL on mobile genetic elements (MGEs). Despite the emergence of CA-MRSA 227 
in carriage in Cambodia,
38
 all the pyomyositis cases were MSSA (Figure 1-figure supplement 228 
1). By applying GWAS methods to a well-powered cohort, our study resolves the controversy 229 
around pyomyositis and PVL, demonstrating strong heritability which localises to a single 230 
region, even when the full bacterial genome is considered. Bacterial GWAS can pinpoint 231 
virulence variants when MGEs act to unravel linkage disequilibrium, if effect sizes are 232 
sufficiently strong. 233 
There is strong biological plausibility for the association demonstrated in this study. PVL is a 234 
well characterised S. aureus toxin, toxic to myeloid cells, which form a first line of defence 235 
against bacterial infection,
20
 and in binding to myeloid cells by a complement receptor (C5aR), 236 
exerts immunomodulatory effects.
22
 The establishment of muscle abscesses is a critical step in 237 
the pathogenesis of pyomyositis, but unlike renal, hepatic and splenic abscesses, skeletal 238 
muscle abscesses are rarely observed in experimental models of bacteraemia, unless there is 239 
preceding muscle trauma.
39
 S. aureus strains containing PVL show increased duration of 240 
 7 
bacteraemia in a rabbit model of sepsis,
33
 and result in larger muscle abscesses.
40
 PVL has been 241 
found strongly bound to necrotic muscle in an individual with myositis associated with 242 
necrotizing fasciitis.
41
 These observations support the hypothesis PVL may facilitate bacterial 243 
seeding to muscles via the bloodstream, and tropism for muscular infection.  244 
These results establish that, for children in Cambodia, staphylococcal pyomyositis is a disease 245 
whose pathogenesis depends crucially on a single toxin. This property is shared by toxin-246 
driven, vaccine-preventable diseases such as tetanus and diphtheria. Therefore, vaccines that 247 
generate neutralising anti-toxin antibodies against PVL
42
 may protect human populations 248 
specifically against this common tropical disease. These results also raise the hypothesis that 249 
antibiotics which decrease toxin expression, and have been recommended in some PVL-250 
associated infections,
43
 may offer specific clinical benefit in treating pyomyositis. More 251 
generally, our study provides an example of how microbial GWAS can be used to elucidate the 252 
pathogenesis of bacterial infections and identify specific virulence genes associated with 253 
human disease.  254 
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Materials and Methods:  255 
Patient sample collection. We retrospectively identified pyomyositis cases from the Angkor 256 
Hospital for Children in Siem Reap, Cambodia, between January 2007 and November 2011. 257 
We screened all attendances in children (≤16 years) using clinical coding (ICD-10 code M60 258 
(myositis)) and isolation of S. aureus from skeletal muscle abscess pus. We reviewed clinical 259 
notes to confirm a clinical diagnosis of pyomyositis was made by the medical staff, and 260 
bacterial strains cultured by routine clinical microbiology laboratory were retrieved from the 261 
local microbiology biobank. 106 clinical episodes of pyomyositis were identified, in 101 262 
individuals, and we included the earliest episode from each individual. 263 
We identified S. aureus nasal colonisation from two cohort studies undertaken at Angkor 264 
Hospital for Children. The first were selected from a collection characterising nasal 265 
colonization in the region between September and October, 2008, which has previously been 266 
described using multi-locus sequence typing.
38
 The swabs had been saved at -80°C since the 267 
study, these samples were re-examined for the presence of S. aureus using selective agar, 268 
confirmed using Staphaurex (Remel, Lenexa, USA) and the DNAse agar test (Oxoid, 269 
Hampshire, UK). Antimicrobial susceptibility testing was performed according to the 2014 270 
Clinical and Laboratory Standards Institute guidelines (M100-24).
44
  271 
We undertook a second cohort study in 2012. Inclusion criteria were children (≤16 years) 272 
attending as an outpatient at Angkor Hospital for Children with informed consent. There were 273 
no exclusion criteria. Children were swabbed between the 2-7th July 2012, using sterile cotton 274 
tipped swabs pre-moistened (with phosphate buffered saline, PBS) using 3 full rotations of the 275 
swab within the anterior portion of each nostril with one swab being used for both nostrils, the 276 
ends were broken into bottles containing sterile PBS and kept cool until plated in the laboratory 277 
(within the hour). The swabs were plated onto Mannitol Salt agar to select for S. aureus. The 278 
M100-24 CLSI
44
 standards were followed for susceptibility testing and bacteria stored in 279 
tryptone soya broth and glycerol at -80°C. 280 
We selected controls from carriers in these two cohorts using the excel randomization function: 281 
222 of 519 from the 2008 cohort and 195 of 261 from the 2012 cohort. 282 
Ethical Framework. Approval for this study was provided by the AHC institutional review 283 
board and the Oxford Tropical Ethics Committee (507-12). 284 
Whole genome sequencing. For each bacterial culture, a single colony was sub-cultured and 285 
DNA was extracted from the sub-cultured plate using a mechanical lysis step (FastPrep; 286 
MPBiomedicals, Santa Ana, CA) followed by a commercial kit (QuickGene; Autogen Inc, 287 
Holliston, MA), and sequenced at the Wellcome Centre for Human Genetics, Oxford on the 288 
Illumina (San Diego, California, USA) HiSeq 2500 platform, with paired-end reads 150 base 289 
pairs long. 290 
A subset of samples were sequenced using long-read sequencing technology. We selected 37 291 
isolates with incomplete assembly upstream of the PVL locus, 22 with ambiguous base calls in 292 
the assembly, and 15 where the region was assembled over 2 contigs. DNA was extracted using 293 
Genomic Tip 100/G (Qiagen, Manchester, UK) and DNA libraries prepared using Oxford 294 
Nanopore Technologies (ONT) SQK-LSK108 library kit (ONT, Oxford, UK) according to 295 
manufacturer instructions. These were then sequenced on ONT GridION device integrated with 296 
a FLO-MIN106 flow cell (ONT, Oxford, UK).  ONT base calling was performed using Guppy 297 
v.1.6. 298 
Variant calling. For short-read sequencing we used Velvet
45
 v1.0.18 to assemble reads into 299 
contigs de novo. Velvet Optimiser v2.1.7 was used to choose the kmer lengths on a per 300 
sequence basis. The median kmer length was 123bp (IQR 119-123). To obtain multilocus 301 
 9 
sequence types we used BLAST
46
 to find the relevant loci, and looked up the nucleotide 302 
sequences in the online database at http://saureus.mlst.net/. Strains that shared 6 of 7 MLST 303 
loci were considered to be in the same Clonal Complex.
47
 Antibiotic sensitivity was predicted 304 
by interrogating the assemblies for a panel of resistance determinants as previously described.
48
  305 
We used Stampy
49
 v1.0.22 to map reads against reference genomes (USA300_FPR3757, 306 
Genbank accession number CP000255.1).
50
 Repetitive regions, defined by BLAST
46
 307 
comparison of the reference genome against itself, were masked prior to variant calling. Bases 308 
were called at each position using previously described quality filters.
 51-53
  309 
After filtering ONT reads with filtlong v.0.2.0 (with settings filtlong -- min_length 1000 --310 
keep_percent 90 --target_bases 500000000 --trim --split 500), hybrid assembly of short 311 
(Illumina) and long (ONT) reads were made, using Unicycler v0.4.5
54
 (default settings).  The 312 
workflow for these assemblies is available at 313 
https://gitlab.com/ModernisingMedicalMicrobiology/MOHAWK) 314 
Reconstructing the phylogenetic tree. We constructed a maximum likelihood phylogeny of 315 
mapped genomes for visualization using RAxML
55
 assuming a general time reversible (GTR) 316 
model. To overcome a limitation in the presence of divergent sequences whereby RAxML fixes 317 
a minimum branch length that may be longer than a single substitution event, we fine-tuned the 318 
estimates of branch lengths using ClonalFrameML.
56
 319 
Kmer counting. We used a kmer-based approach to capture non-SNP variation.
1
 Using the de 320 
novo assembled genome, all unique 31 base haplotypes were counted using dsk
57
. If a kmer 321 
was found in the assembly it was counted present for that genome, otherwise it was treated as 322 
absent. This produced a set of 10,744,013 variably present kmers, with the presence or absence 323 
of each determined per isolate. We identified a median of 2,801,000 kmers per isolate, 324 
including variably present kmers and kmers common to all genomes (IQR 2,778,000-325 
2,837,000). 326 
Calculating heritability. We used the Genome-wide Efficient Mixed Model Association tool 327 
(GEMMA
31
) to fit a univariate linear mixed model for association between a single phenotype 328 
(pyomyositis vs asymptomatic nasal carriage). We calculated the relatedness matrix from 329 
kmers, and used GEMMA to estimate the proportion of variance in phenotypes explained by 330 
genotypic diversity in the sample set (i.e. estimated heritability). Heritability estimates with and 331 
without a covariate (e.g. the presence of high risk kmers) are compared by testing for difference 332 
in proportions. We use the point estimate for heritability as the denominator to calculate the 333 
relative decrease proportion.  334 
Genome wide association testing of Kmers. We performed association testing using an R 335 
package bacterialGWAS (https://github.com/jessiewu/bacterialGWAS), which implements a 336 
published method for locus testing in bacterial GWAS.
3
 The association of each kmer on the 337 
phenotype was tested, controlling for the population structure and genetic background using a 338 
linear mixed model (LMM) implemented in GEMMA.
24
 The parameters of the linear mixed 339 
model were estimated by maximum likelihood and likelihood ratio test was performed against 340 
the null hypothesis (that each locus has no effect) using the software GEMMA.
24
 GEMMA was 341 
run using a minor allele frequency of 0 to include all SNPs. GEMMA was modified to output 342 
the ML log-likelihood under the null, and alternative and –log10 p values were calculated using 343 
R scripts in the bacterialGWAS package. Unadjusted odds ratios were reported because there 344 
was no residual heritability unexplained by the most significant kmers. 345 
To address the possibility of differing effect sizes between the two control cohorts, we have 346 
repeated the analysis after splitting the study into two groups – early (2008 and earlier, n = 276, 347 
 10 
cases n =54, controls n = 222) and late (2009 and later, n=242, cases n=47, controls n=195). 348 
We then examined the maximum likelihood estimates produced by the LMM for kmers 349 
mapping to the PVL coding sequence in each region. The 95% CI of the estimate from each sub 350 
study were overlapping (See Figure 2-figure supplement 4).  351 
Testing for lineage effects. We tested for associations between lineage and phenotype using an 352 
R package bugwas (available at https://github.com/sgearle/bugwas), which implements a 353 
published method for lineage testing in bacterial GWAS.
3
 We tested lineages using principal 354 
components. These were computed based on biallelic SNPs using the R function prcomp. To 355 
test the null hypothesis of no background effect of each principal component, we used a Wald 356 
test, which we compared against a χ2 distribution with one degree of freedom to obtain a p 357 
value. 358 
Kmer mapping. We used Bowtie
58
 to align all 31bp kmers from short-read sequencing were to 359 
a draft reference (the de novo assembly of a CC-121 pyomyosits strain PYO2134). Areas of 360 
homology between the draft reference and well-annotated reference strains were identified by 361 
aligning sequences with Mauve.
59
 For all 31bp kmers with significant association with case-362 
controls status, the likely origin of the kmer was determined by nucleotide sequence BLAST
46 
363 
of the kmers against a database of all S. aureus sequences in Genbank.  364 
Joint short-read and long-read analysis. 31bp kmers were counted for the 37 hybrid short-read 365 
and long-read assemblies using dsk
57
. The presence or absence of all Illumina (short-read) 366 
kmers that mapped to the two PVL toxin-coding sequences and the upstream intergenic region 367 
plus the surrounding 1kb were reassessed. For the 37 samples with hybrid assemblies, the 368 
presence/absence of these kmers was determined from the kmers counted from the hybrid 369 
assemblies. For all other samples, presence/absence was determined from the kmers counted 370 
from the short-read only assemblies. The new presence/absence patterns were tested for 371 
association with the phenotype controlling for population structure and genetic background 372 
using GEMMA
31
, using the same relatedness matrix as the original short-read analysis. 373 
Predicting presence of PVL genes and bacteriophages. We used BLAST to check for the 374 
relative coverage of the PVL CDS (From reference genome USA300_FPR3757 (CP000255.1) 375 
positions 1546170-1548350), as well as the entire sequence of 6 known PVL positive phages 376 
(2958(NC_011344.1), PVL (NC_002321.1), PVL108 (NC_008689.1), SLT 377 
(NC_002661.2), Sa2MW (NC_003923.1), Sa2USA (CP000255.1))18, as well as the 378 
hypothesised prophage region from PYO2134 (1571177- 1616957), which we have 379 
calledCC121. For PVL genes, we determined relative coverage of the query sequence; over 380 
98% coverage was used as threshold for gene presence. 
 
381 
Multiple testing correction. Multiple testing was accounted for by applying a Bonferroni 382 
correction;
60
 the individual locus effect of a variant (kmer or PC) was considered significant if 383 
its P value was smaller than α/np, where we took α = 0.05 to be the genome-wide false-positive 384 
rate and np to be the number of kmers or PCs with unique phylogenetic patterns, that is, unique 385 
partitions of individuals according to allele membership. We identified 236627 unique kmer 386 
patterns and 518 PCs, giving thresholds of 2.1 x10
-7
and 9.7x10
-5
 respectively.  387 
Data availability. Sequence data has been submitted to Short Read Archive (Bioproject ID 388 
PRJNA418899). Clinical origins of sequenced strains are listed in supplementary information 389 
(Supplementary File 4). 390 
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Figure 1. Phylogeny of S. aureus cultured from children in Cambodia shows strong strain-to-598 
strain variation in pyomyositis prevalence. The phylogeny was estimated by maximum 599 
likelihood from SNPs mapping to the USA300 FPR3757 reference genome. Multi-locus 600 
sequence type (ST) or clonal complex (CC) groups are shown (outer grey ring). Case/control 601 
status is marked in the middle ring: pyomyositis (gold, n = 101) or nasal carriage (green, n = 602 
417). Branches of the phylogeny that correspond to the three principal components (PCs) 603 
significantly associated with case/control status (PCs 1, 2 and 20) are marked in red, blue and 604 
yellow, respectively. Branch lengths are square root transformed to aid visualization. The 605 
presence of the kmers most strongly associated with pyomyositis is indicated by red blocks in 606 
the inner ring 607 
Figure 1-figure supplement 1 Sampling frequencies of the major strains were stable over 608 
time. The year of sampling (2007-2008, blue shaded lines) and MRSA status (orange lines) 609 
are illustrated around the phylogeny of the bacteria sampled from pyomyositis cases (gold 610 
lines) and asymptomatic carriage controls (green lines). The three PCs most significantly 611 
associated with case/control status are also shown (PCs 1, 2 and 20 by red, blue and yellow 612 
branches respectively). Branch lengths are square root transformed to aid visualization.   613 
Figure 2. Kmers associated with pyomyositis. (A) All kmers (n = 10,744,013) were mapped 614 
to the genome assembly of one CC121 pyomyositis bacterium (PYO2134). Each point 615 
represents a kmer, plotted by the mapped location and the significance of the association with 616 
disease (-log10 p value). Kmers are coloured by the odds ratio (OR) of kmer presence for 617 
disease risk. A Bonferroni-adjusted threshold for significance is plotted in grey (B) The 618 
region between 1.57-1.62 MB in greater detail. Grey arrows depict coding sequences, 619 
determined by homology to USA300 FPR3757. (C) Associations for kmers mapping to 620 
region 1,571 – 1,574kB is plotted. Kmer presence determined from hybrid assembly using 621 
short and long-read data for assembly. Grey arrows depict coding sequences, determined by 622 
homology to USA300 FPR3757. 623 
 624 
Figure 2-figure supplement 1: Alignments of reference genome PYO2134 assembly (R) 625 
with 37 de novo assemblies of Illumina short-read sequencing (C) which feature either 626 
ambiguities (Ns) or contig boundaries in the region 389bp upstream of PVL coding sequence. 627 
Contig boundaries, when overlapping, are marked with a red diamond. Ns in the assembly are 628 
marked in dark grey. Polymorphisms are colour-coded by base. 629 
 630 
Figure 2-figure supplement 2: Alignments of reference genome PYO2134 assembly (R) 631 
with 37 de novo assemblies of Illumina short-read sequencing (C) which feature either 632 
ambiguities (Ns) or contig boundaries in the region 389bp upstream of PVL coding sequence. 633 
Contig boundaries, when overlapping, are marked with a red diamond. Ns in the assembly are 634 
marked in dark grey. Polymorphisms are colour-coded by base. 635 
Figure 2-figure supplement 3: Presence of PVL and potential PVL carrying phages across 636 
the population. Multi-locus sequence type (ST) or clonal complex (CC) groups are shown 637 
(outer grey ring). Case/control status is marked in the next outermost ring: pyomyositis (gold, 638 
n = 101) or nasal carriage (green, n = 417). Branch lengths are square root transformed to aid 639 
visualization. The presence of kmers mapping to the PVL coding sequence (dark red) or of 640 
>98% coverage of PVL coding sequence in de novo assembly found by BLAST (red) are 641 
marked in the next rings. Phages with >95% coverage on BLAST of the de novo assembly 642 
are marked by points (phiPVL in purple, SaUSA2 in dark blue, SLT in light blue and 643 
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CC121 in orange), and bars are used to mark the phage with the greatest sequence 644 
homology.  645 
 646 
Figure 2-figure supplement 4: Significant association between case/control status and the 647 
presence of kmers mapping to PVL was consistent across early and late subsets.  Results 648 
from repeat kmer GWAS using early and late sub-groups of cases and controls, as well as 649 
results from original GWAS of the entire group. We report the presence of kmers mapping 650 
across the PVL locus in each subset. Forest plot showing the effect sizes (box) with 95% CI 651 
(whiskers) determined by LMM for kmers mapping to PVL kmer in each subset, and in the 652 
complete study (diamond centred on effect size extending across 95% CI).  The statistical 653 
significance of association with case/control status after controlling for population structure is 654 
shown for each subset and the complete study.  655 
 656 
Supplementary File 1: Isolates included in this study. 657 
Supplementary File 2: All significant kmers from short read sequencing assembly, evidence 658 
of association, frequency, location on mapping to the study reference PYO2134, best match 659 
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Subgroup
Before 2009
2009 and after
All
PVL kmers
(cases)
51
47
PVL kmers
(controls)
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Significance
(−log10 p value)
12.9
18.5
17.9
−0.2 0 0.2 0.4 0.6 0.8
Maximum	likelihood	estimate	of	
effect	size	in	LMM	
